Evidence map›Paper›PMID 30599062›Full record

ArticleHeart and vessels2019

Associations between plasma nesfatin-1 levels and the presence and severity of coronary artery disease.

Susumu Ibe, Yoshimi Kishimoto, Hanako Niki, Emi Saita, Tomohiko Umei, Kotaro Miura, Yukinori Ikegami, Reiko Ohmori, Kazuo Kondo, Yukihiko Momiyama

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Adipokine Nesfatin-1 Mediates Endothelial Dysfunction by SuppressingJournal of the American Heart Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. "Sibling" battle or harmony: crosstalk between nesfatin-1 and ghrelin.Cellular and molecular life sciences : CMLS · 2022
    Review
  6. Observational
  7. Article
  8. Adipokines and Inflammation: Focus on Cardiovascular Diseases.International journal of molecular sciences · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Susumu IbeDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Yoshimi KishimotoEndowed Research Department "Food for Health", Ochanomizu University, Tokyo, Japan.
Hanako NikiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Emi SaitaEndowed Research Department "Food for Health", Ochanomizu University, Tokyo, Japan.
Tomohiko UmeiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Kotaro MiuraDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Yukinori IkegamiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Reiko OhmoriFaculty of Regional Design, Utsunomiya University, Tochigi, Japan.
Kazuo KondoEndowed Research Department "Food for Health", Ochanomizu University, Tokyo, Japan.
Yukihiko MomiyamaDepartment of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan. ymomiyamajp@gmail.com.ORCID http://orcid.org/0000-0002-7710-1446

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nesfatin-1 is a recently identified anorexigenic peptide mainly secreted from the brain and adipose tissue. Although nesfatin-1 may have pro-inflammatory and apoptotic properties, the association between plasma nesfatin-1 levels and coronary artery disease (CAD) has not been clarified yet. We investigated plasma nesfatin-1 levels in 302 patients undergoing elective coronary angiography. Of the 302 study patients, CAD was present in 172 (57%), of whom 67 had 1-vessel, 49 had 2-vessel, and 56 had 3-vessel disease. Compared with 130 patients without CAD, 172 with CAD had higher plasma nesfatin-1 levels (median 0.21 vs. 0.17 ng/mL, P < 0.01). A stepwise increase in nesfatin-1 levels was found depending on the number of > 50% stenotic coronary vessels: 0.17 in CAD(-), 0.20 in 1-vessel, 0.21 in 2-vessel, and 0.22 ng/mL in 3-vessel disease (P < 0.05). A high nesfatin-1 level (> 0.19 ng/mL) was found in 43% of patients with CAD(-), 55% of those with 1-vessel, 55% of those with 2-vessel, and 68% of those with 3-vessel disease (P < 0.05). Nesfatin-1 levels significantly correlated with the number of > 50% stenotic coronary segments (r = 0.14, P < 0.02). In multivariate analysis, plasma nesfatin-1 levels were a significant factor for CAD independent of atherosclerotic risk factors. The odds ratio for CAD was 1.71 (95% CI 1.01-2.91) for high nesfatin-1 level of > 0.19 ng/mL (P < 0.05). Thus, plasma nesfatin-1 levels were found to be high in patients with CAD and were associated with CAD independent of atherosclerotic risk factors, suggesting that high nesfatin-1 levels in patients with CAD may play a role in the development of coronary atherosclerosis.

Indexed as

AgedAged, 80 and overAtherosclerosisBiomarkersCalcium-Binding ProteinsCoronary Artery DiseaseCoronary StenosisDiabetes ComplicationsDNA-Binding ProteinsFemaleHumansHypertensionJapanLinear ModelsLogistic ModelsMaleBiomarkersCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNUCB2 protein, humanNucleobindinsAtherosclerosisBiomarkerCoronary artery diseaseNesfatin-1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.